In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

The trial is enrolling people as young as 18 who have few or no detectable Alzheimer's-related molecular changes in their brains, up to 25 years before the expected onset of dementia symptoms, to ...

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves ...

“The woman had reached an age when most individuals with Down syndrome develop dementia symptoms, yet she remained cognitively stable,” says Jr-Jiun Jean Liou, PhD, lead study author and a ...

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia,” co-senior author Dr. Randall Bateman, a professor of neurology ...

Opens in a new tab or window Removing amyloid appeared to delay Alzheimer's symptoms in asymptomatic patients ... 10.1016/S1474-4422(25)00024-9. Source Reference: Schott JM "Amyloid immunotherapy ...

An experimental treatment appears to delay Alzheimer’s disease symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing ...

which is our best biomarker measure of Alzheimer’s symptoms and dementia,” co-senior author Randall J. Bateman, MD, said in a news release. “In clinical practice right now, we don’t have ...

The tests help doctors diagnose the neurodegenerative condition in people with symptoms but don't indicate the degree of impairment in thinking or memory due to Alzheimer’s dementia. Current ...